In Some Good News For India, We May Have An Approved COVID-19 Vaccine By First Quarter Of 2021

India, just like the rest of the world is desperately waiting for a COVID-19 vaccine, and around the world, there have been several promising candidates at various stages of approval.

India is on course to have an "approved" vaccine within the first quarter of calendar year 2021 and Pune based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is well placed to deliver the first vaccine, according to a report from Bernstein Research, a top Wall Street research and brokerage firm.

REUTERS

Four global candidates closer to approval

"Globally, there are four candidates that are close to an approval by the end of the CY2020 or early 2021. Through partnerships India has access to two of those - AZ/Oxford's viral vector vaccine and Novavax's protein sub-unit vaccine with AZ/Oxford's vaccine ahead by a quarter," says the Bernstein report.

"With their existing capabilities and capacities SII is best positioned to commercialise one or both of the partnered vaccine candidates depending on approval timing, capacities and pricing."

BCCL

Data from Phase 1 and Phase trials look promising for both these candidates "in terms of safety and the vaccines ability to elicit an immune response". The way things look now, the report indicates that both vaccine candidates "will require two doses to be administered 21/28 days apart".

2021 looks likely for vaccine

The report strikes an upbeat tone on India's "global capacity equation" and does not foresee "manufacturing scale up challenges".

Serum Institute of India, the report says, could supply 600 million doses in 2021 and 1 billion doses in 2022, out of which 400 to 500 million "should be available in India in 2021" in the context of the company's commitments to Gavi The Vaccine Alliance and lower and middle income markets.

AFP

The report estimates that vaccine volumes will be split 55:45 between the government and private market.

"We believe the government channel will have first access to the capacities but also believe there will be a sizable private market. In terms of funding, manpower and delivery infrastructure the Government will struggle to shoulder the burden on its own and we expect the private market to step in and supplement."

SII has announced that Gavi will procure vaccines at $3 per dose. The Bernstein report uses that as a benchmark to estimate procurement price to be around $3 a dose for the government and end consumer price of about $6 per dose.

Apart from SII, the report lists at least three other Indian pharma companies - Zydus, Bharat Biotech and Biological E - which are working on their own vaccine candidates and are currently in Phase 1 and 2.

REUTERS/ REPRESENTATIONAL IMAGE

Between SII, Bharat Biotech, Biological E, and some smaller players, India produces around 2.3 billion doses of various vaccines every year.

SII alone is the globally largest manufacturer of vaccines with 1.5 billion doses capacity. Every two out of three children globally gets a shot manufactured by SII.